All the latest worldwide HIV and AIDS news, including treatment, prevention, and hepatitis and TB co-infections. News from our own team of writers plus articles we have selected from other sources.

aidsmap hiv & aids news


hiv & aids news selected from other sources

  • History of HIV and AIDS
    A mystery illness killed a boy in 1969. Years later, doctors learned what it was: AIDS
    New Zealand Herald | 16 May 2019

    The 16-year-old boy had the kind of illness that wouldn't be familiar to doctors for years: He was weak and emaciated, rife with stubborn infections and riddled with rare cancerous lesions known as Kaposi's sarcoma, a skin disease found in elderly men of Mediterranean descent. The boy, Robert Rayford, died on May 15, 1969, in St. Louis. It would be more than a decade before doctors started seeing similar cases among gay men in New York and California. In 1982, with the numbers of sick surging, the disease got a name: Acquired Immune Deficiency Syndrome.

  • Men who have sex with men (MSM)
    UNAIDS calls on countries to remove discriminatory laws and enact laws that protect people from discrimination
    UNAIDS | 16 May 2019

    Ahead of the International Day against Homophobia, Transphobia and Biphobia (IDAHOT), on 17 May, UNAIDS is calling on all countries to remove discriminatory laws against lesbian, gay, bisexual, transgender and intersex (LGBTI) people. Discriminatory laws drive key populations out of reach of critical health and social services.

  • Medical procedures and other blood-borne exposure
    Hundreds of Pakistanis infected with HIV after doctor used contaminated dirty syringes
    South China Morning Post | 16 May 2019

    Pakistan was long considered a low prevalence country for HIV, but the disease is expanding at an alarming rate. The country currently has the second fastest growing HIV rates across Asia, according to the UN.

  • Cancer
    FDA's Breakthrough Designation Granted for Kaposi Sarcoma Therapy
    Pharmacy Times | 15 May 2019

    Celgene’s pomalidomide (Pomalyst) has been granted Breakthrough Therapy designation by the FDA for the treatment of patients with previously-treated HIV-positive Kaposi sarcoma (KS) and patients with HIV-negative KS, according to a press release.

  • Pharmaceutical industry
    Gilead tries—and fails—to dodge lawsuit claiming it delayed safer HIV meds
    Fierce Pharma | 15 May 2019

    Gilead Sciences has faced years of allegations that it sidelined its safer, next-gen HIV drugs to reap as much revenue as possible from the older generation before the new meds hit. And a federal judge has allowed one set of those allegations—filed by 140 patients from 31 states—to proceed.

  • Harm reduction
    Bolsonaro Cuts Harm Reduction, Escalates Drug War
    Filter | 15 May 2019

    Largely unreported in English-language news media, Brazilian President Jair Bolsonaro has pulled the plug on government support for harm reduction, instead calling for the promotion of abstinence and a crackdown on people who use and sell drugs.

  • Harm reduction
    New research finds heating drug use equipment linked to decreased HIV risk
    CATIE | 15 May 2019

    Researchers found HIV was transmitted more through drug cookers than needles. Heating drug use equipment was found to reduce the risk of infection

  • Clinical trials
    UCSD has not told women with HIV of data breach, despite researchers' pleas
    inewsource | 15 May 2019

    University of California San Diego officials stonewalled attempts to notify women in an HIV research study that their confidential data was breached more than seven months ago, an inewsource investigation has found. UCSD researchers conducting the EmPower Women study told university officials in October that participants’ names, audio-taped conversations and other sensitive materials were made accessible to everyone working at Christie’s Place, a San Diego nonprofit supporting women with HIV and AIDS.

  • Pharmaceutical industry
    Gilead struck anti-competitive deals to bolster profits on an HIV drug, lawsuit says
    STAT | 15 May 2019

    In a bid to maintain its dominance in the HIV market, Gilead Sciences (GILD) allegedly conspired with other drug makers whose medicines were part of a so-called combination cocktail in order to block generic competition, according to a lawsuit filed by AIDS activists and two unions.

  • PrEP policies and guidelines
    Statement on Gilead’s Announcement of PrEP Donation
    AVAC | 14 May 2019

    Gilead’s donation is an acknowledgment that there is a huge issue with PrEP access in America, as in many parts of the world. We welcome this indication that the company grasps the gravity of the situation. However, we urgently need a lower price for all. It’s disappointing that even this small step has taken so long.

Conference news

News from the 25th Annual Conference of the British HIV Association (BHIVA).


Sign up for our Sexual Health & HIV Policy EUROBulletin.

HIV update

Sign up for HIV update, our fortnightly news bulletin for people living with HIV in the UK.


Watch our AIDS 2018 aidsmapLIVE panel discussion on YouTube.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.